The results showed that fingolimod significantly attenuated motor function deficits in both PD mouse models, reduced the loss of nigral tyrosine hydroxylase-positive neurons, decreased striatal dopamine and metabolite levels, and maintained ERK phosphorylation levels while decreasing cleaved caspase 3 expression (Zhao et al., 2017). The gene discussed is CASP3; the disease is Parkinson disease.